Compare PRTC & NQP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRTC | NQP |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.3M | 449.2M |
| IPO Year | N/A | N/A |
| Metric | PRTC | NQP |
|---|---|---|
| Price | $17.22 | $11.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.4K | ★ 168.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.30 | $10.65 |
| 52 Week High | $20.00 | $12.22 |
| Indicator | PRTC | NQP |
|---|---|---|
| Relative Strength Index (RSI) | 47.75 | 41.11 |
| Support Level | $16.51 | $11.83 |
| Resistance Level | $18.10 | $12.17 |
| Average True Range (ATR) | 0.49 | 0.07 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 39.80 | 26.92 |
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Nuveen Pennsylvania Quality Municipal Income Fund is a closed-end fixed income mutual fund. The fund's investment objectives are (i) to provide current income exempt from regular federal income tax, the federal alternative minimum tax applicable to individuals and California income tax and (ii) to enhance portfolio value relative to the municipal bond market by investing in tax- exempt municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser, believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The fund prominenty invests in tax-exempt municipal bonds from Pennsylvania that are investment grade.